Immunotoxins, formulations thereof and their use in medicine

A pharmaceutical composition comprising:

• (i) 0.05 to 0.5 mg/mL, optionally 0.2 mg/mL, of a monoclonal antibody molecule that specifically recognises CD3 and which is conjugated to at least one ricin toxin A (RTA), and/or
• 0.05 to 0.5 mg/mL, optionally 0.2 mg/mL, of a monoclonal antibody molecule that specifically recognises CD7 and which is conjugated to at least one RTA;
• (ii) 5 to 20 mM, optionally 10 mM, of a citrate buffer;
• (iii) 50 to 300 mM, optionally:
• a) 75 to 200 mM;
• or b) 125 mM, of L-arginine or a pharmaceutically acceptable salt thereof;
• (vi) 0.01 to 0.1% (w/v), optionally 0.05% (w/v), of a polysorbate,
• wherein the composition is in water and has a pH in the range 6 to 7.5, optionally 6.5.